Healthcare - Press Releases

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Report on how AI is redefining market landscape - The global online therapy services marketsize is estimated to grow by USD 64.09 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of 53.9% during the forecast period. Surging adoption of smartphones coupled with increased preference for online servicesis driving market growth,with a trend towardsgrowing popularity of online health services. However,privacy concerns related to patient mental health issues poses a challenge. Key market players include 7 Cups of Tea Co., American Well Corp., BreakThrough Counseling Services, Calmerry, CareMe Health, Cerebral Inc., Doctor On Demand Inc., DocVita Inc., Felicity, Heart it out, HopeQure Wellness Solutions Pvt. Ltd., Manastha, MDLIVE Inc., Mental Fuel Inc., Mind Voyage, ReGain, TALKSPACE INC., Teladoc Health Inc., ThriveTalk, and Thriveworks Counseling.

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) applicationfor HBM9378/SKB378 (also known as WIN378), a fully human antibody targeting thymic stromal lymphopoietin (TSLP), forthe treatment ofchronic obstructive pulmonary disease (COPD).

TAICHUNG, Feb. 5, 2025 /PRNewswire/ -- Healthcare Expo Taiwan is a professional-oriented exposition involving healthcare, information/communication, technology, biopharmaceutical and medical device industries. Attended by healthcare professionals from all over the world, the Expo showcases the latest developments and trends in healthcare technology in Taiwan. China Medical University (CMU) and Healthcare System unveiled groundbreaking advancements in AI-driven drug discovery and cancer therapy at the latest 8th Healthcare Expo. These achievements cement CMU and Healthcare System's position as a global leader in healthcare innovation, setting new benchmarks for the biomedical industry.

NEW YORK, Feb. 5, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The globalproton pump inhibitors (PPIs) marketsize is estimated to grow by USD 819.5 million from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of 4.7% during the forecast period. Reformulation of drugsis driving market growth,with a trend towardsgrowing geriatric population. However,increasing lawsuits against PPIs poses a challenge. Key market players include Amgen Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bausch Health Companies Inc., Bayer AG, Cipla Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson Inc., Perrigo Co. Plc, Pfizer Inc., RedHill Biopharma Ltd., Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., The Procter and Gamble Co., and Zydus Lifesciences Ltd..

STOCKHOLM, Feb. 5, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its report for the fourth quarter 2024.

STOCKHOLM, Feb. 5, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its report for the fourth quarter 2024.

MILAN, Feb. 5, 2025 /PRNewswire/ -- Newronika, the developer of groundbreaking adaptive deep brain stimulation technology, is proud to announce the receipt of an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA). The IDE clearance paves the way for Newronika to initiate a pivotal U.S. clinical trial to evaluate the safety and efficacy of its adaptive DBS system for patients with movement disorders, including Parkinson's disease.

MAILAND, 5. Februar 2025 /PRNewswire/ --Newronika, der Entwickler der bahnbrechenden adaptiven Technologie zur Tiefenhirnstimulation, ist stolz darauf, den Erhalt einer IDE (Investigational Device Exemption) von der US-amerikanischen Food and Drug Administration (FDA) bekannt zu geben. Die IDE-Freigabe ebnet Newronika den Weg fr den Beginn einer entscheidenden klinischen Studie in den USA, um die Sicherheit und Wirksamkeit seines adaptiven DBS-Systems fr Patienten mit Bewegungsstrungen, einschlielich der Parkinson-Krankheit, zu bewerten.

TURIN, Italy, Feb. 5, 2025 /PRNewswire/ -- GruppoMAIP are pleased to announce their participation in the innovative ReGenesis protocol from Studio Lisa Tavazzani, which is changing how luxury goods are managed. This system focuses on improving the handling of unsold products and production waste from high-end manufacturing, transforming them into valuable resources through advanced upcycling methods.

LONDRES, MUNICH et NEW DELHI, 5 fvrier 2025 /PRNewswire/ --Datar Cancer Genetics (DCG) lance Exacta AI, une plateforme multianalyte de nouvelle gnration pilote par l'IA qui fournit des options de traitement optimises pour les patients atteints de cancer qui ont puis les options standard. La plateforme fournit un bilan tumoral 360et une analyse de donnes assiste par l'IA pour dcoder les donnes complexes de l'interactome tumoral, y compris les donnes molculaires (SNG : ADN+ARN), protomique, gnomique, fonctionnelle et clinique, ce qui permet de proposer des options thrapeutiques personnalises avec une analyse approfondie des risques et des avantages. Exacta AI traite en temps rel les donnes de laboratoire humide et les intgre aux connaissances provenant de sources multiples pour valuer la synergie, les interactions, la toxicit et les contre-indications des conjugus anticorps-mdicaments (CAM), des inhibiteurs de points de contrle, des thrapies cibles, des agents endocriniens, des agents chimiothrapeutiques et des mdicaments raffects. La plateforme peut recommander jusqu' dix combinaisons de traitements multi-mdicamenteux fonds sur des donnes probantes pour valuation par des oncologues ou des experts en profilage molculaire des tumeurs, offrant un nouvel espoir l o il n'existe pas de norme de soins pour les patients atteints de cancers rfractaires ou rcurrents.

-Datar Cancer Genetics presenta una plataforma de soporte de decisiones basada en inteligencia artificial y con mltiples analitos de prxima generacin para el tratamiento personalizado de cnceres difciles de tratar

HELSINKI, Feb. 5, 2025 /PRNewswire/ -- UPM-Kymmene CorporationStock Exchange Release (Other information disclosed according to the rules of the Exchange) 5 February 2025 at 08:20EET

KOPENHAGEN, Dnemark, 5. Februar 2025 /PRNewswire/ -- Eine Brustkrebsdiagnose verndert das Leben der Betroffenen auf einen Schlag, und der Weg durch die Behandlung kann oft berfordern. Von der Bewltigung komplexer Therapien ber die Bewltigung von Nebenwirkungen bis hin zum Kontakt mit rzten und Pflegepersonal - Patientinnen stehen praktisch tglich vor groen Herausforderungen. Um diese Herausforderungen besser zu bewltigen, stellt Dawn Health in Zusammenarbeit mit Novartis jetzt Cora BC vor, eine innovative App, die alle Brustkrebspatientinnen und ihre Angehrigen unabhngig von ihrem Stadium oder der Art ihrer Behandlung auf ihrem Weg untersttzen soll.

COPENHAGUE, Dinamarca, 5 de febrero de 2025 /PRNewswire/ --Recibir un diagnstico de cncer de mama es un momento que cambia la vida y el proceso de tratamiento puede resultar abrumador. Desde gestionar terapias complejas y afrontar los efectos secundarios hasta mantenerse en contacto con los proveedores de atencin mdica, los pacientes se enfrentan a desafos importantes todos los das. Para ayudar a abordar estos desafos,Dawn Health se enorgullece de presentar Cora BC en colaboracin con Novartis, una aplicacin transformadora diseada para apoyar a todos los pacientes con cncer de mama y a sus seres queridos, independientemente de su etapa o tratamiento, a lo largo de su proceso.

COPENHAGEN, Denmark, Feb. 5, 2025 /PRNewswire/ -- Receiving a breast cancer diagnosis is a life-changing moment, and the journey through treatment can often feel overwhelming. From managing complex therapies and coping with side effects to staying connected with healthcare providers, patients face significant challenges every day. To help address these challenges, Dawn Health is proud to introduce Cora BC in collaboration with Novartis, a transformative app designed to support all breast cancer patients and their loved ones irrespective of their stage or treatment throughout their journey.

COPENHAGUE, Danemark, 5 fvrier 2025 /PRNewswire/ -- Recevoir un diagnostic de cancer du sein est un moment qui change la vie, et le voyage travers le traitement peut souvent sembler accablant. Qu'il s'agisse de grer des thrapies complexes, de faire face aux effets secondaires ou de rester en contact avec les prestataires de soins de sant, les patientes sont confrontes chaque jour des dfis de taille. Pour aider relever ces dfis, Dawn Health est fire de prsenter Cora BC en collaboration avec Novartis, une application transformatrice conue pour soutenir toutes les patientes atteintes d'un cancer du sein et leurs proches, quel que soit leur stade ou leur traitement, tout au long de leur parcours.

ZWINGENBERG, Germany, Feb. 4, 2025 /PRNewswire/ -- Akribion Therapeutics ("Akribion"), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the completion of a Seed Financing round raising EUR 8 million to accelerate the development of novel therapeutics based on Akribion's proprietary G-dase E nucleases.

BOSTON and LAUSANNE, Switzerland, Feb. 4, 2025 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces that the U.S. Food and Drug Administration (FDA) and Health Canada have cleared the Investigational New Drug (IND) / Clinical Trial Application (CTA) for the study of ALY-101 in patients suffering from Alopecia Areata (AA).

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The globalVitamin D testing marketsize is estimated to grow by USD 182.6 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over4.96% during the forecast period. Growing awareness of importance of vitamin D to health and immunityis driving market growth,with a trend towardsincreasing prevalence of infections and autoimmune diseases. However,product recalls posing challenges to manufacturers poses a challenge. Key market players include Beckman Coulter Inc., Biohit Oyj, bioMerieux SA, BioVendor Laboratorni medicina AS, Boditech Med Inc., DiaSorin SpA, DiaSys Diagnostic Systems GmbH, Everly Health Inc., F. Hoffmann La Roche Ltd., Laboratory Corp. Of America Holdings, Qualigen Therapeutics Inc., Quest Diagnostics Inc., Quidelortho Corp., Randox Laboratories Ltd., Recipe Chemicals and Instruments GmbH, Revvity Inc., Siemens AG, Tecan Trading AG, Thermo Fisher Scientific Inc., and Tosoh Corp..

LONDON, Feb. 4, 2025 /PRNewswire/ --The leveraged finance and private equity communities came together on 29 January 2025 for the inaugural Leveraged Finance Fights Melanoma (LFFM) London benefit and cocktail party at The National Gallery. Building on the success of the flagship event in New York City, the London benefit for the Melanoma Research Alliance(MRA) marked a significant milestone in expanding the LFFM franchise into an international platform, with over 600 attendees and raising GBP1.4 million to support MRA's investments in UK-based scientists pursuing high impact, lifesaving melanoma research.

LONDON, Feb. 4, 2025 /PRNewswire/ --The leveraged finance and private equity communities came together on 29 January 2025 for the inaugural Leveraged Finance Fights Melanoma (LFFM) London benefit and cocktail party at The National Gallery. Building on the success of the flagship event in New York City, the London benefit for the Melanoma Research Alliance(MRA) marked a significant milestone in expanding the LFFM franchise into an international platform, with over 600 attendees and raising GBP1.4 million to support MRA's investments in UK-based scientists pursuing high impact, lifesaving melanoma research.

GOUSTRANVILLE, France, 4 fvrier 2025 /PRNewswire/ -- L'cole nationale vtrinaire d'Alfort (EnvA) est fire d'annoncer le lancement officiel des activits du Centre Hospitalier Universitaire Vtrinaire quin (Chuv-Eq), sur le site du Campus International du Cheval, en Normandie. Ce nouveau centre constitue une tape majeure dans le dveloppement des soins, la formation et la recherche en sant quine.

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Report on how AI is redefining market landscape - The globalbiologics contract development and manufacturing organization (CDMO) marketsize is estimated to grow by USD 16.32 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of 13.7% during the forecast period. Availability of cost-efficient resources in emerging marketsis driving market growth,with a trend towardsadvent of big data. However,capacity utilization and constraints poses a challenge. Key market players include 3P Biopharmaceuticals, AbbVie Inc., AGC Biologics, Binex Co. Ltd., Boehringer Ingelheim International GmbH, Bora Pharmaceuticals, Catalent Inc., Evonik Industries AG, FUJIFILM Corp., Grifols SA, J RETTENMAIER and SOHNE GmbH and Co KG, JSR Corp., Kemwell Biopharma Pvt. Ltd., Lonza Group Ltd., Novartis AG, Rentschler Biopharma SE, Samsung Electronics Co. Ltd., Shenzhen Hepalink Pharmaceutical Co. Ltd., Toyobo Co. Ltd., and WuXi Biologics Cayman Inc..

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT) of a class action securities lawsuit.

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Report on how AI is redefining market landscape - The global snus marketsize is estimated to grow by USD 1.197 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of about10.7% during the forecast period. Availability of flavored snusis driving market growth,with a trend towardschanging consumption trends in global snus market. However,negative health effects of snus consumption poses a challenge. Key market players include Altria Group Inc., Another Snus Factory Stockholm AB, British American Tobacco Plc, Dholakia Tobacco Pvt. Ltd., Empire of Snus, GN Tobacco Sweden AB, Harsh International, Imperial Brands Plc, Japan Tobacco Inc., Philip Morris International Inc., Swisher International Inc., TIGERSNUSORGANIC SNUS TOBACCO, Turning Point Brands Inc., and Wilsons and Co. Sharrow Ltd..